437 related articles for article (PubMed ID: 16904873)
1. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Cantón R; Lode H; Graninger W; Milkovich G
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
[TBL] [Abstract][Full Text] [Related]
2. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Sollet JP
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
Grossman RF; Rotschafer JC; Tan JS
Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
[TBL] [Abstract][Full Text] [Related]
5. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
7. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
10. Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
Lode H
Int J Clin Pract Suppl; 2002 Mar; (125):10-17; discussion 37-9. PubMed ID: 12014852
[TBL] [Abstract][Full Text] [Related]
11. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Tennenberg AM; Davis NB; Wu SC; Kahn J
Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin for the treatment of respiratory tract infections.
Torres A; Liapikou A
Expert Opin Pharmacother; 2012 Jun; 13(8):1203-12. PubMed ID: 22594848
[TBL] [Abstract][Full Text] [Related]
13. [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
Płusa T
Pol Merkur Lekarski; 2011 Feb; 30(176):91-6. PubMed ID: 21544977
[TBL] [Abstract][Full Text] [Related]
14. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin in the treatment of community-acquired pneumonia.
Noreddin AM; Elkhatib WF
Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
[TBL] [Abstract][Full Text] [Related]
16. New insights in the treatment by levofloxacin.
File TM
Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
[TBL] [Abstract][Full Text] [Related]
17. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
20. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]